



Geneva, July 24, 2013

2013 HALF-YEAR PRESS RELEASE

Activity

Revenues for the first six months of the year grew 16% compared to 1H2012, in line with management expectations and in spite of continued price pressure in Southern and Eastern Europe as well as in the US.

Direct sales revenues grew 12% with sales in the US growing 21%.

International sales to distributors grew 19% with revenues in EMEA growing 39%, revenues in Latin America growing 2% and revenues in Asia growing 10%. Sales in Latin America were negatively impacted by the reinforcement of protectionist measures in various South American countries but are oriented positively for the second part of the year.

As part of its strategy to address core markets, Spineart opened a direct sales subsidiary in Italy in February 2013.

During the first part of the year, Spineart hosted various international bioskills labs in English, Spanish, French and for the first time Russian languages. These sessions focused on Spineart state-of-the-art technology platforms in motion and MIS.

Recruitments in R&D, medical affairs, marketing and sales team were performed during the first semester resulting in a 20% increase in Spineart headcount.

Technology Platforms

In June 2013, Spineart initiated a limited release of its new ROMEO^{®2} 25D deformity screw and ROMEO^{®2} 25T trauma screw. The ROMEO^{®2} 25D comes as an addition to Spineart's deformity platform (ROMEO^{®2} LC) and the ROMEO^{®2} 25T as an addition to Spineart's MIS percutaneous thoraco-lumbar fixation platform (ROMEO^{®2} MIS).

Also to support the increasing adoption of Spineart's deformity platform, a new generation of pre-assembled cross-links for long constructs as well as "quick-release" reducer tubes will be launched in the second half of 2013.

Prospects

As expected 2013 is proving to be an important year for the commercial development of Spineart with a confirmed double-digit growth in the first half of the year.

On July 1, 2013, Spineart opened a direct sales subsidiary in Germany to progressively take over the activities of Sanofi Spine. Germany is the largest European market for spinal implants and this subsidiary is expected to make an important contribution to Spineart's direct sales growth for the second part of the year.

The direct sales teams in France and Switzerland have been extended and this should also progressively contribute to the growth of our direct sales revenues over the coming months. Spineart is now direct in the US, Germany, France, Switzerland, Italy and Austria and further announcements are expected to be made before the end of the year.

Finally Spineart is planning to launch additional devices in the US and OUS in the coming months.

About Spineart

Spineart delivers pioneering, safe and efficient solutions to spine surgeons, operating room teams and patients.

Spineart, present in 47 countries, offers a full range of high quality Swiss Made Fusion, Motion, and MIS devices worldwide, focusing on simplicity and safety of use.

Spineart markets a complete portfolio of traceable barcoded sterile packed implants and is thereby proudly promoting higher safety, cost-efficiency, and compliance at the hospital.

For more information please contact us at contact@spineart.com or visit spineart.com.